MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Väisänen, S.
Right arrow Articles by Mäenpää, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Väisänen, S.
Right arrow Articles by Mäenpää, P. H.

Vol. 62, Issue 4, 788-794, October 2002

Structurally and Functionally Important Amino Acids of the Agonistic Conformation of the Human Vitamin D Receptor

Sami Väisänen, Sanna Ryhänen, Janne T. A. Saarela, Mikael Peräkylä, Teemu Andersin, and Pekka H. Mäenpää

Departments of Biochemistry (S.V., S.R., T.A., P.H.M.) and Chemistry (J.T.A.S., M.P.), University of Kuopio, Kuopio, Finland

The crystal structures of the ligand binding domain of human vitamin D receptor (VDR) complexed with its natural ligand or the superagonists MC1288 or KH1060 have recently been reported. The crystallized ligand binding domain (LBD) of VDR, however, differs from the full-length VDR with respect to deletion of 50 amino acids between its helices 2 and 3. In this study, we investigated structurally and functionally important amino acid interactions within the ligand binding pocket of the full-length VDR in the presence of several synthetic vitamin D3 analogs. We used site-directed mutagenesis scanning combined with limited proteolytic digestion, electrophoretic mobility shift assay, and reporter gene assay and correlated the findings with the crystal structures of truncated VDR LBD. Our results suggest that structurally different agonists have distinct ligand-receptor interactions and that the amino acid residues H229, D232, E269, F279, and Y295 are critical for the agonistic conformation of the VDR. Our biological data, which were obtained with the full-length VDR, fit well with the crystal structure of the truncated VDR LBD and suggest that removal of the insertion domain between helices 2 and 3 of the receptor does not markedly influence the functionality of the VDR.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
F. Molnar, M. Perakyla, and C. Carlberg
Vitamin D Receptor Agonists Specifically Modulate the Volume of the Ligand-binding Pocket
J. Biol. Chem., April 14, 2006; 281(15): 10516 - 10526.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. Perakyla, M. Malinen, K.-H. Herzig, and C. Carlberg
Gene Regulatory Potential of Nonsteroidal Vitamin D Receptor Ligands
Mol. Endocrinol., August 1, 2005; 19(8): 2060 - 2073.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. M. Gonzalez, P. Samenfeld, M. Perakyla, and C. Carlberg
Corepressor Excess Shifts the Two-Side Chain Vitamin D Analog Gemini from an Agonist to an Inverse Agonist of the Vitamin D Receptor
Mol. Endocrinol., October 1, 2003; 17(10): 2028 - 2038.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Vaisanen, M. Perakyla, J. I. Karkkainen, M. R. Uskokovic, and C. Carlberg
Structural Evaluation of the Agonistic Action of a Vitamin D Analog with Two Side Chains Binding to the Nuclear Vitamin D Receptor
Mol. Pharmacol., June 1, 2003; 63(6): 1230 - 1237.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics